Image 1_Subcutaneous foslevodopa/foscarbidopa initiation in a Parkinson’s day-clinic - a suitable setting to ensure treatment efficacy, tolerability and psychosocial adaption.tif
Background<p>Subcutaneous foslevodopa/foscarbidopa (LDp/CDp) has expanded the treatment options in advanced Parkinson’s disease (aPD). However, the most appropriate therapeutic setting for therapy implementation is not clear.</p>Objective<p>To present a concept for LDp/CDp therapy...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , |
| Published: |
2025
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|